| Date Filed | Type | Description |
| 08/11/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 33.7% stake in VOR BIOPHARMA INC. |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/09/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 05/26/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/14/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/14/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/14/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/14/2023 |
8-K
| Quarterly results |
| 03/23/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/14/2023 |
SC 13G/A
| Paradigm Biocapital Advisors LP reports a 9.9% stake in Vor Biopharma Inc. |
| 01/10/2023 |
SC 13G/A
| FMR LLC reports a 12.1% stake in VOR BIOPHARMA INC |
| 12/21/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 12/14/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 12/14/2022 |
8-K
| Termination of a Material Definitive Agreement Interactive Data |
| 12/09/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 34.8% stake in VOR BIOPHARMA INC. |
| 12/08/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 12/07/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement, by and among Vor Biopharma Inc. and Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated, as representatives of the several underwriters named therein",
"Opinion of Cooley LLP",
"Securities Purchase Agreement, by and between Vor Biopharma Inc. and RA Capital Healthcare Fund, L.P",
"Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million" |
|
| 12/07/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 11/29/2022 |
8-K
| Regulation FD Disclosure Interactive Data |
| 11/14/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 28.8% stake in VOR BIOPHARMA INC. |
| 10/27/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 06/17/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/28/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/14/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/21/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/14/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 03/14/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/09/2022 |
SC 13G/A
| FMR LLC reports a 8.5% stake in VOR BIOPHARMA INC |
| 11/10/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 08/09/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
|